HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The effect of CA1 dopaminergic system in harmaline-induced amnesia.

Abstract
In the present study, the effects of bilateral injections of dopaminergic drugs into the hippocampal CA1 regions (intra-CA1) on harmaline-induced amnesia were examined in male mice. A one-trial step-down passive avoidance task was used for the assessment of memory retention in adult male mice. Pre-training intra-peritoneal (i.p.) administration of harmaline (1 mg/kg) induced impairment of memory retention. Moreover, intra-CA1 administration of dopamine D1 receptor antagonist, SCH23390 (0.02 μg/mouse), dopamine D1 receptor agonist, SKF38393 (0.5 μg/mouse), dopamine D2 receptor antagonist, sulpiride (1 μg/mouse) and dopamine D2 receptor agonist, quinpirole (0.25 and 0.5 μg/mouse) suppressed the learning of a single-trial passive avoidance task. Also, pre-training intra-CA1 injection of subthreshold doses of SCH23390 (0.001 μg/mouse) or sulpiride (0.25 μg/mouse) with the administration of harmaline (1 mg/kg, i.p.) reversed impairment of memory formation. However, pre-training intra-CA1 injection of SKF38393 (0.1 μg/mouse) or quinpirole (0.1 μg/mouse) increased pre-training harmaline (0.25 and 0.5 mg/kg, i.p.)-induced retrieval impairment. Moreover, SKF Ca blocker (SKF) (0.01 μg/mouse) decrease the amnesia induced by harmaline (1 mg/kg), while co-administration of SKF (0.01 μg/mouse)/sulpiride (0.25 μg/mouse) or SCH23390 (0.001 μg/mouse)/sulpiride (0.25 μg/mouse) potentiate amnesia caused by harmaline. These findings implicate the involvement of CA1 dopaminergic mechanism in harmaline-induced impairment of memory acquisition.
AuthorsM Nasehi, M Ketabchi, F Khakpai, M-R Zarrindast
JournalNeuroscience (Neuroscience) Vol. 285 Pg. 47-59 (Jan 29 2015) ISSN: 1873-7544 [Electronic] United States
PMID25446354 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 IBRO. Published by Elsevier Ltd. All rights reserved.
Chemical References
  • Benzazepines
  • Dopamine Agonists
  • Dopamine Antagonists
  • Monoamine Oxidase Inhibitors
  • Receptors, Dopamine D1
  • Receptors, Dopamine D2
  • SCH 23390
  • 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
  • Sulpiride
  • Harmaline
  • Dopamine
Topics
  • 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine (pharmacology)
  • Amnesia (chemically induced, drug therapy, metabolism)
  • Animals
  • Avoidance Learning (drug effects, physiology)
  • Benzazepines (pharmacology)
  • CA1 Region, Hippocampal (drug effects, metabolism)
  • Dopamine (metabolism)
  • Dopamine Agonists (pharmacology)
  • Dopamine Antagonists (pharmacology)
  • Harmaline (toxicity)
  • Male
  • Memory (drug effects, physiology)
  • Mice
  • Monoamine Oxidase Inhibitors (toxicity)
  • Receptors, Dopamine D1 (metabolism)
  • Receptors, Dopamine D2 (metabolism)
  • Sulpiride (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: